Abstract
Background/Aims: Chemotherapy combined with radiation therapy is the standard treatment for limited stage small cell lung cancer (LS-SCLC). Although numerous studies indicate that the overall duration of chemoradiotherapy is the most relevant predictor of outcome, the optimal chemotherapy and radiation schedule for LS-SCLC remains controversial. Therefore we analyzed the time from the start of any treatment until the end of radiotherapy (SER) in patients with LS-SCLC. Methods: We retrospectively analyzed 29 patients diagnosed histologically with LS-SCLC and divided them into two groups: a short SER group (< 60 days) and a long SER (> 60 days) group. Patients were treated with irinotecan-based chemotherapy and thoracic radiotherapy. Results: Sixteen patients were in the short SER group and 13 patients were in the long SER group. Short SER significantly prolonged survival rate (p = 0.03) compared with that of long SER. However, no significant differences in side effects were observed. Conclusions: Short SER should be considered to improve the outcome of concurrent chemoradiotherapy for LS-SCLC.
Original language | English |
---|---|
Pages (from-to) | 449-455 |
Number of pages | 7 |
Journal | Korean Journal of Internal Medicine |
Volume | 28 |
Issue number | 4 |
DOIs | |
Publication status | Published - 2013 Jul |
Keywords
- Chemoradiotherapy
- Limited-stage
- Small cell lung carcinoma
- Start of any treatment until the end of radiotherapy
ASJC Scopus subject areas
- Internal Medicine